MedTrace Logo

Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

NCT01290341 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 860

Last updated 2013-09-26

Study results available
· View outcomes & findings →

Summary

This is a 6-week, double-blind, randomized, placebo-controlled, multicenter, parallel group Phase 3 study of NAFT-600 applied once a day for 2 weeks compared to vehicle (placebo) in the treatment of tinea pedis.

Conditions

  • Tinea Pedis

Interventions

DRUG

NAFT-600 (naftin 2 % gel)

Topical; applied once daily for two weeks

DRUG

Placebo

Topical; applied once daily for two weeks.

Sponsors & Collaborators

  • Merz North America, Inc.

    lead INDUSTRY

Principal Investigators

  • Lawrency Parrish, MD · Paddington Testing Co., Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-11-30
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01290341 on ClinicalTrials.gov